Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 83,934 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Not applicable Interventional

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

NCT03291951
View directory record Official record
Conditions
Resistance Training, Colon Cancer, Chemotherapy Effect
Interventions
Resistance training
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Oakland, California • Boston, Massachusetts • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 30, 2026, 4:09 PM EDT
Withdrawn Phase 1 Interventional

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

NCT02526329
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
donor regulatory T lymphocytes, laboratory biomarker analysis
Biological · Other
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT02824029
View directory record Official record
Conditions
Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Psychosocial Support for Acute Hospital Pain and Distress

NCT02590029
View directory record Official record
Conditions
Acute Pain
Interventions
Mindfulness, Suggestion, Psychoeducation
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional

The Digital Incentive Spirometer (DIS): Improving Adherence to Incentive Spirometry

NCT03686631
View directory record Official record
Conditions
Post-Op Infection, Adherence, Patient, Pulmonary Atelectasis, Incentive Spirometry, Post-Op Complication
Interventions
Smartphone Arm
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Active Choice in the EHR to Promote Statin Therapy

NCT03271931
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Active choice, Passive choice
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD

NCT02391402
View directory record Official record
Conditions
Traumatic Brain Injury, Posttraumatic Stress Disorder
Interventions
Cognitively Augmented Behavioral Activation, Treatment as Usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional Results available

ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)

NCT02600845
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
ACCU-CHEK
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Montgomery, Alabama • Huntington Beach, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 4:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Interventions
Pimicotinib(ABSK021), Placebo
Drug
Lead sponsor
Abbisko Therapeutics Co, Ltd
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Beverly Hills, California • Durham, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 3 Interventional

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

NCT00069745
View directory record Official record
Conditions
Prostate Cancer, Hormone Refractory Prostate Cancer
Interventions
Satraplatin, Prednisone
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
105
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia

NCT06021795
View directory record Official record
Conditions
Insomnia
Interventions
Sound Treatment
Device
Lead sponsor
Third Wave Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional

OrthoCor Advanced Trial for Knee Osteoarthritis

NCT06475677
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteo Arthritis Knee
Interventions
OrthoCor Advanced System
Device
Lead sponsor
Caerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

NCT04532177
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fat Reduction in the Flanks Area vs. Control

NCT02465775
View directory record Official record
Conditions
Flanks Fat Reduction vs. Control
Interventions
UltraShape treatment
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Metairie, Louisiana • Hunt Valley, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1 Interventional Results available

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

NCT03542175
View directory record Official record
Conditions
Breast Cancer
Interventions
Rucaparib, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

NCT03520842
View directory record Official record
Conditions
KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Methotrexate, Pharmacokinetic Study, Regorafenib
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 3 Interventional Results available

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01134042
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder, Placebo Inhalation Powder 1, Placebo Inhalation Powder 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

NCT06926673
View directory record Official record
Conditions
Neoplasms
Interventions
Dostarlimab, Belrestotug., Nelistotug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

NCT00477269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 30, 2026, 4:09 PM EDT
Completed No phase listed Observational

Coping Strategies Used by Food Insecure Households

NCT02767141
View directory record Official record
Conditions
Food Insecurity
Interventions
Coping Strategies
Behavioral
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Asheboro, North Carolina • Clarkton, North Carolina • Elizabethtown, North Carolina + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 1 Interventional

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354
View directory record Official record
Conditions
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
Interventions
CLBR001 and SWI019
Combination Product
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 4 Interventional

Cognitive and Behavioral Effects of Lacosamide

NCT01175954
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
Evan Fertig
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Stress Management (CBSM) & Prostate Cancer

NCT05486754
View directory record Official record
Conditions
Stress
Interventions
Cognitive behavioral stress management, Psychoeducational Control
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 30, 2026, 4:09 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

NCT00332605
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Naltrexone plus N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 30, 2026, 4:09 PM EDT